Skip to main navigation Skip to search Skip to main content

Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science